Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01906112
Other study ID # 17_2013RC_IN305
Secondary ID
Status Withdrawn
Phase Phase 3
First received July 15, 2013
Last updated February 26, 2015
Start date August 2013
Est. completion date August 2019

Study information

Verified date February 2015
Source National Cancer Institute, Thailand
Contact n/a
Is FDA regulated No
Health authority Thailand: Ministry of Public Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine benefits of surgery for the primary in patients with breast cancer stage IV in randomized controlled study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 2019
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Healthy breast cancer stage IV patients with resectable primary breast tumor.

- Resectable breast cancer stage IV patients who well response of visceral metastasis to systemic therapy and fit for surgery.

Exclusion Criteria:

- Breast cancer stage IV patients with local complication of primary breast tumor that require surgery for palliation such as uncontrolled bleeding,large and non-healing ulcer or intractable pain.

- Breast cancer stage IV patients with unresectable primary breast tumor or extensive chest wall disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Surgery for primary breast tumor.
Complete resection of primary breast tumor(Lumpectomy or mastectomy)

Locations

Country Name City State
Thailand Division Head & Neck and Breast, Department of Surgery. Faculty of Medicine Siriraj Hospital Bangkok Noi Bangkok
Thailand Department of Surgery, Faculty of Medicine Vajira Hospital. Dusit Bangkok
Thailand Khon Kaen University Muang Khon Kaen
Thailand Chonburi Cancer Hospital Muang Chonburi Chonburi
Thailand Suratthani Cancer Hospital Muang Suratthani Suratthani
Thailand Udon Thani Cancer Hospital Muang Udon Thani Udon Thani
Thailand Phyathai 2 Hospital PhyaThai Bangkok
Thailand National Cancer Institute Ratchathewi Bangkok
Thailand Phramongkutklao Hospital Ratchathewi Bangkok

Sponsors (2)

Lead Sponsor Collaborator
National Cancer Institute, Thailand Vichaiyut Hospital

Country where clinical trial is conducted

Thailand, 

References & Publications (6)

Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007 Aug;14(8):2187-94. Epub 2007 May 24. — View Citation

Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002 Oct;132(4):620-6; discussion 626-7. — View Citation

Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010 Mar 1;116(5):1226-33. doi: 10.1002/cncr.24873. — View Citation

Nguyen DA, Truong PT, Lesperance ML et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Proceedings of 53rd Annual Meeting of the American Society for Radiation Oncology. Int. J. Radiat. Oncol. Biol. Phys. (2011)

Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006 Jun 20;24(18):2743-9. Epub 2006 May 15. — View Citation

Shien T, Kinoshita T, Shimizu C, Hojo T, Taira N, Doihara H, Akashi-Tanaka S. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009 Mar;21(3):827-32. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Five years No
Secondary Quality of life & Uncontrolled chest wall disease Five years No
See also
  Status Clinical Trial Phase
Completed NCT03511781 - Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer N/A
Completed NCT00199212 - PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 Phase 1
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Active, not recruiting NCT02755272 - A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Phase 2
Withdrawn NCT02140437 - Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Phase 2
Terminated NCT02183805 - Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer Phase 2
Terminated NCT01531764 - BIBW 2992 (Afatinib) and Vinorelbine Phase 2
Completed NCT00669565 - Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Recruiting NCT02161315 - Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer N/A
Completed NCT00433095 - Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer Phase 2